Hello! Welcome to the official website of Betta Pharmaceuticals!
Adhering to an innovative development philosophy to benefit the people, Betta Pharmaceuticals commits to the new drug development to achieve scientific innovation for the people, create more affordable medicines, and make people live better.
Copyright ? 2019 All Rights Reserved Betta Pharmaceuticals Co., Ltd.
浙ICP備11052940號-2
C4 Therapeutics (C4T) is a clinical-stage biopharmaceutical company focused on targeting the science of protein degradation to create a new generation of drugs that will change patients' lives. C4T is using its TORPEDO? platform to effectively design and optimize small molecule drugs that use the body's natural protein recycling system to rapidly degrade disease-causing proteins, potentially overcoming drug resistance. C4T is advancing multiple targeted oncology programs to the clinical stage and expanding its research platform to deliver more drugs for hard-to-treat diseases.
On May 30, 2023, Betta Pharmaceuticals entered into a collaboration with C4 Therapeutics, Inc. (C4T) (NASDAQ: CCCC). Betta Pharmaceuticals acquired the right to develop, manufacture and commercialize CFT8919 in China (including Hong Kong, Macau and Taiwan) and to receive an agreed percentage of sales commission outside the aforementioned regions.
C4 Therapeutics
InventisBio, founded by U.S. returned Ph.D.s at Shanghai Zhangjiang HiTech Park in 2013, is a rapidly growing biotech company focusing on the development of innovative medicines targeting on tumor and metabolic diseases. The company currently has 4 candidate drugs targeting tumor and gout. Except for D-0316, there are 2 other candidates under phase I clinical trials in China and the U.S.. Furthermore, InventisBio also focuses on the drug development to combine with other immunotherapies.
On December 28th, 2018, Betta Pharma reached a strategic collaboration agreement with InventsBio Inc. on the development and commercialization of D-0316 in China (including mainland, Hongkong and Taiwan).
InventisBio
Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies, and proprietary cancer vaccine platforms. Agenus has more than 26 years of experience in the development of immuno-oncology therapies and has entered into equity investments agreements as well as licensing agreements with several multinational pharmaceutical companies. The U.S. biopharmaceutical companies Incyte Corporation (NASDAQ: INCY) and Gilead Sciences, Inc. (NASDAQ: GILD) are both stockholders of Agenus and are also key collaborators of Agenus.
On June 22, 2020, Betta Pharmaceuticals Co., Ltd. announced that it has entered into an agreement with Agenus Inc. that Betta has obtained an exclusive right to develop and commercialize Balstilimab (a PD-1 mAb) and Zalifrelimab (a CTLA-4 mAb) in all uses (excluding intravesical delivery), as a monotherapy or combination therapy with other components in Greater China (including Hong Kong, Macao and Taiwan). In the meantime, Betta shall purchase Agenus’ newly-issued shares, to strength the collaboration of both parties.
Agenus
Mabworks is a national high-tech enterprise founded by a team of overseas returnees focusing on the antibody design and research, clinical development and commercialization. Mabworks has a leading antibody discovery and development platform. Its MIL60 program, currently in the stage of clinical study, is targeting vascular endothelial growth factor (VEGF), and is being developed for 7 solid tumor indications including non-small cell lung cancer, colorectal cancer and breast cancer.
On February 28th, 2017, Betta Pharma reached an agreement with Beijing Mabworks to collaborate on the MIL60 program, expanding Betta Pharma’s biologics pipeline.
Mabworks
Located in Florida, U.S., Xcovery is a biopharmaceutical company focusing on the discovery and development of innovative medicines for advanced tumor treatment and improvement of cancer patient care. Xcovery has built up an oncology pipeline that targets multiple malignant diseases. The leading product, ensartinib hydrochloride (X-396), is a small molecule ALK inhibitor to treat ALK+ NSCLC patients.
On October 25th, 2014, Betta Pharma invested 20 million US dollars in Xcovery to jointly develop a next-generation ALK inhibitor X-396 (ensartinib hydrochloride).
On July 26th, 2017, Betta Pharma increased the holdings of Xcovery and became its controlling shareholder. Betta Pharma and Xcovery are jointly advancing the global clinical development of X-396 (ensartinib hydrochloride).
Xcovery
Located in Shanghai, Anew Pharma is an innovative pharmaceutical company founded by overseas returnees, focusing on the development of the targeted therapy CM082. With the innovative business model and booming CRO clusters in China, Anew Pharma integrates various sources and applying them on innovative drug development.
On February 26th, 2017, Betta Pharma invested 370 million RMB to acquire 77.4% of Anew Pharmaecuticals Co., Ltd., and took over the development of vorolanib (CM082).
On June 16th, 2017, Betta Pharma acquired Anew Pharma, and owned the China right of vorolanib.
Anew
Tyrogenex is a U.S. biotech company dedicated to discover and develop multi-kinase inhibitors targeting angiogenesis to treat solid tumor indications. Tyrogenex discovered a novel antitumor small molecule compound, which is a dual-target inhibitor of vascular endothelial growth factor receptor (VEGFR) and human platelet-derived growth factor receptor (PDGFR).
On August 25th, 2017, Betta Pharma signed an agreement with Tyrogenex Inc. in Washington D.C. to co-develop the oncology indications of vorolanib in ex-China regions.
Tyrogenex
Merus focuses on the clinical development of tumor immunotherapeutics, and has established the Biclonics? platform to develop innovative human bispecific antibodies. Based on the immunoglobulin IgG, the Biclonics? platform produces bispecific antibodies that have met industry standards. Through pre-clinical and clinical studies, the antibodies produced by this platform were found to share similar characteristics with conventional monoclonal antibodies, such as long half-life and low immunogenicity.
On December 11th, 2018, Betta Pharma reached a strategic collaboration agreement with Merus and obtained the exclusive right to develop and commercialize MCLA-129 in China.
Merus
The mission of Repugene is to integrate precision medicine into public healthcare, developing gene sequencing technology and products. The services provided by Repugene include regular health checkup, oncogene screening and detection, research collaboration, data processing and cloud computing, artificial intelligence, immunotherapy, companion diagnostics for pharmaceutical research and development, bioinformatics analysis and etc.. Driven by its scientific collaboration, technology innovation and product development, Repugene strives for providing better clinical solutions to patients and healthcare institutes, promoting the development of the precision medicine industry.
On February 26th, Betta Pharma signed a strategic collaboration agreement with Repugene, strengthening their collaboration on precision medicine.
Repugene
Meryx focuses on the discovery and development of small molecule immuno-oncology therapeutics, dedicating its R&D efforts to the development of kinase inhibitors targeting Mer, to treat hematologic and solid tumor indications.
On Juy 17th, 2017, Betta Pharma reached a strategic collaboration agreement with Meryx and obtained the exclusive right to develop and commercialize MRX-2843 in China (including mainland China, Hong Kong, Taiwan and Macau).
Meryx
Beijing Biostar Biotechnologies, Ltd. was established in Haidian Park, Zhongguancun Science and Technology Zone, Beijing in July 2002. It is a national high-tech enterprise led by a team of U.S. returnees, focusing on the discovery, technology transfer and consultation of anticancer small molecule drugs. Its leading product UTD1 is a national first-class oncology innovative drug, and it is also the first new epothilone-based anticancer drug approved for clinical trials in China, indicating Biostar’s advanced R&D capabilities.
In May, 2017, Betta Pharma invested in Beijing Biostar Technologies, Ltd.
Biostar
Hangzhou DAC Biotech is a Chinese biotech company jointly founded by U.S. returnees-comprised entrepreneurs’ team, Zhejiang pharmaceutical enterprises and venture capital firms in Yuhang, Hangzhou, 2012. The core team is built up with 5 Ph.D. returnees and 36 Ph.D. and M.A. recruited in China. Hangzhou DAC Biotech focuses on developing and commercializing antibody-conjugated drugs for targeted cancer treatments.
In December, 2015, Betta Pharma invested in Hangzhou DAC Biotech.
DAC
Based in Binjiang, Hangzhou, HanX Biopharmaceuticals is an innovative biopharmaceutical company with a senior executive team comprised of overseas returnees and industry veterans, focusing on the research and development of innovative antibody therapeutics. As of now, HanX has set up the development and commercialization platforms adhering to global standards, and developed a pipeline targeting tumor, autoimmune disease, inflammation and cardiovascular disease.
In January, 2017, Betta Pharma invested in HanX Biopharmaceuticals.
HanX
Amgen is focusing on the discovery, development, manufacturing and sales of innovative drugs, and it is devoted to benefit patients with unmet medical needs. Since its establishment in 1980, Amgen has become one of the global leading biotech companies providing innovative drugs for millions of patients in more than 100 countries and regions. The strong pipeline and the global-leading production level of Amgen ensure its quality supply as well as its leadership in biologics production. Through its scientists’ research on key disease metabolisms, Amgen develops multiple leading innovative biotherapeutics and establishes itself as a leader in the global biotechnology field.
On May 10th, 2013, Betta Pharma signed a collaboration contract with Amgen to promote the Vectibix in China.
Amgen
Equinox Science LLC is a joint venture founded by Betta Pharma and Tyrogenex in Newcastle, DE, U.S. in 2017, focusing on the co-development of vorolanib (X-82) for cancer treatments. As of now, Equinox Sciences owns the global rights of vorolanib (X-82) in oncology and ophthalmology indications except for China, and the business scope includes the development, manufacturing, commercialization and marketing of vorolanib.
In January, 2017, Betta Pharma established Equinox Sciences LLC in joint venture with Tyrogenex.
Equinox Sciences
主站蜘蛛池模板：
一二三四影视在线看片免费|
黄色网站软件app在线观看免费|
91久久成人免费|
亚洲国产美国国产综合一区二区|
人妻在线日韩免费视频|
久久国产成人亚洲精品影院|
国产精品免费αv视频|
一级特级aaaa毛片免费观看|
久久亚洲精品成人无码|
一级做a爰片久久免费|
亚洲综合最新无码专区|
a在线视频免费观看|
亚洲一区二区三区电影|
色影音免费色资源|
亚洲人av高清无码|
亚洲av无码天堂一区二区三区|
一级毛片大全免费播放下载
|
国产精品成人免费视频网站京东|
亚洲一区二区三区播放在线|
在线观看AV片永久免费|
国产亚洲精品VA片在线播放|
免费被黄网站在观看|
一级毛片免费毛片毛片|
国产亚洲精品成人AA片新蒲金|
人妖系列免费网站观看|
国产亚洲大尺度无码无码专线|
国产一区二区三区免费观在线|
亚洲一区二区三区偷拍女厕|
在线涩涩免费观看国产精品|
77777_亚洲午夜久久多人|
在线免费视频一区|
大地影院MV在线观看视频免费|
亚洲欧洲国产日韩精品|
97视频免费在线|
亚洲av午夜电影在线观看|
国产午夜亚洲精品国产成人小说|
成在线人免费无码高潮喷水|
久久精品国产精品亚洲艾草网
|
一级女人18片毛片免费视频|
中文字幕亚洲综合久久菠萝蜜
|
亚洲国产综合在线|
